-transparent.png){kind=logo}
Two separate studies were performed with 12 volunteers in order to demonstrate the bioequivalence of 2 piroxicam (CAS 36322-90-4) tablet and 2 piroxicam suppository formulations after single dose administration. A validated reversed-phase HPLC method with UV-detection is described. Bioequivalence assessment was done by using the posterior probability of a mean ratio between 0.8 and 1.2, and by using the Two One-Sided Tests Procedure (i.e. the 90% confidence interval). The probability approach and the confidence interval approach were compared.
Related Publications
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
November 2008,
International journal of clinical pharmacology and therapeutics,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
July 2012,
Arzneimittel-Forschung,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
January 2006,
Arzneimittel-Forschung,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
January 2007,
Arzneimittel-Forschung,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
January 2001,
Arzneimittel-Forschung,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
February 1988,
Bollettino chimico farmaceutico,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
January 2011,
Drug design, development and therapy,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
May 2005,
International journal of pharmaceutics,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
January 2006,
Arzneimittel-Forschung,
Y Michotte, and
H P Van Klaveren, and
M R Detaevenier, and
C F Gusdorf, and
Vanhaelst
February 1989,
DICP : the annals of pharmacotherapy,
